Stocks of PLx Pharma Inc. (NASDAQ:PLXP) traded higher last session on Wall Street, down -6.77% to $0.19.
According to the data, PLx Pharma Inc. (NASDAQ:PLXP) has 1 analysts covering its stock. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $21.00 and a low of $21.00, we find $21.00. Given the previous closing price of $0.20, this indicates a potential upside of 10400.0 percent. PLXP stock price is now -46.01% away from the 50-day moving average and -88.34% away from the 200-day moving average. The market capitalization of the company currently stands at $5.90M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
A total of 1 analysts have issued a hold rating and 0 have given it a buy rating. Brokers who have rated the stock have averaged $21.00 as their price target over the next twelve months.
With the price target maintained at $14, Raymond James recently Upgraded its rating from Mkt Perform to Outperform for PLx Pharma Inc. (NASDAQ: PLXP). On September 21, 2021, BWS Financial recently initiated its ‘Buy’ rating on the stock quoting a target price of $29, while ‘Oppenheimer’ rates the stock as ‘Outperform’.
In other news, Giordano Natasha, Chief Executive Officer bought 4,100 shares of the company’s stock on Mar 15. The stock was bought for $14,977 at an average price of $3.65. Upon completion of the transaction, the Chief Executive Officer now directly owns 5,186 shares in the company, valued at $985.34. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 15, Chief Financial Officer O’Connor Rita M bought 13,700 shares of the business’s stock. A total of $50,122 was incurred on buying the stock at an average price of $3.66. This leaves the insider owning 26,670 shares of the company worth $5067.3. A total of 15.39% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PLXP stock. A new stake in PLx Pharma Inc. shares was purchased by AVANTAX PLANNING PARTNERS, INC. during the first quarter worth $2,000. In total, there are 55 active investors with 31.20% ownership of the company’s stock.
Friday’s opening bell rang with an opening price of $0.2000 for PLx Pharma Inc. (NASDAQ: PLXP). During the past 12 months, PLx Pharma Inc. has had a low of $0.13 and a high of $7.93. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.80, and a quick ratio of 4.30. The fifty day moving average price for PLXP is $0.3446 and a two-hundred day moving average price translates $1.6102 for the stock.
The latest earnings results from PLx Pharma Inc. (NASDAQ: PLXP) was released for Jun, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.43, beating analysts’ expectations of -$0.56 by 0.13. This compares to -$0.80 EPS in the same period last year. The company reported revenue of $0.39 million for the quarter, compared to $6.62 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -94.17 percent. For the current quarter, analysts expect PLXP to generate $1.3M in revenue.
PLx Pharma Inc.(PLXP) Company Profile
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company’s lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.
